Study on the Safety and Effects of ORG-129 in Patients with Fibrostenotic Crohn’s Disease

2 1

What is this study about?

This clinical trial is focused on studying the effects of a new treatment for fibrostenotic Crohn’s disease, a condition where parts of the digestive system become narrowed due to inflammation and scarring. The treatment being tested is a medication called AGMB-129, which is taken in capsule form. The study will compare the effects of AGMB-129 to a placebo to understand its safety and how it works in the body.

The purpose of the study is to evaluate the safety and tolerability of AGMB-129 in patients with fibrostenotic Crohn’s disease. Participants will be randomly assigned to receive either AGMB-129 or a placebo. The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving the actual medication or the placebo. This helps ensure that the results are not biased. The study will take place over a period of time, with regular check-ups to monitor the participants’ health and any changes in their condition.

Throughout the study, various health assessments will be conducted, including checking for any side effects, performing clinical laboratory tests, and monitoring heart health through an electrocardiogram (ECG). The study will also look at how AGMB-129 is processed in the body and its effects on certain genes in the intestinal lining. The goal is to gather comprehensive information about the treatment’s safety and its potential benefits for people with fibrostenotic Crohn’s disease.

1 initial assessment

Upon joining the study, an initial assessment is conducted to confirm eligibility. This includes a review of medical history and current symptoms related to fibrostenotic Crohn’s disease.

Eligibility is based on specific criteria, such as having a diagnosis of Crohn’s disease with at least one stricture in the terminal ileum and stable symptoms.

2 randomization and treatment assignment

Participants are randomly assigned to receive either the investigational medication AGMB-129 or a placebo. This process is double-blind, meaning neither the participant nor the study team knows which treatment is being administered.

The medication is provided in capsule form and is taken orally.

3 treatment period (part a)

The treatment period lasts for 12 weeks. During this time, participants take the assigned medication daily.

Regular monitoring is conducted to assess safety and any potential side effects. This includes clinical laboratory tests, electrocardiograms (ECGs), and physical examinations.

4 evaluation at week 12

At the end of the 12-week treatment period, a comprehensive evaluation is performed. This includes assessing any adverse events, changes in vital signs, and other health indicators.

Participants’ responses to the treatment are also evaluated through various tests, including a 2-D echocardiogram.

5 continuation of treatment (part b)

Participants who complete the initial 12-week period and are eligible may continue treatment in Part B of the study.

Continuation is based on the investigator’s judgment and the participant’s willingness to proceed.

6 ongoing monitoring

Throughout the study, ongoing monitoring is conducted to ensure participant safety and to gather data on the effects of AGMB-129.

This includes tracking pharmacokinetic parameters, which involve how the drug is absorbed, distributed, metabolized, and excreted by the body.

Who Can Join the Study?

Must have a diagnosis of ileal or ileocolonic Crohn’s Disease. This means the disease affects the last part of the small intestine or both the small and large intestines. The diagnosis should be based on medical guidelines and confirmed at least 3 months before joining the study.
Must have at least one stricture in the terminal ileum. A stricture is a narrowing of the intestine. It should be confirmed by a special scan called MRE. The stricture should not be too severe and should be caused by Crohn’s Disease.
Must have obstructive symptoms that are manageable. This means symptoms like blockage in the intestine should not be severe enough to need hospital treatment or surgery. The person should be able to eat enough food, even if they need to change their diet, and maintain a stable weight for 4 weeks before joining the study.
Must be on a stable treatment plan for Crohn’s Disease and agree to continue this treatment during the study.
For Part B of the study: Must have completed the 12-week treatment period in Part A and be willing and able to continue treatment.
For Part B of the study: The doctor must believe the participant can continue or restart treatment after finishing Part A.
Participants can be of any gender.
Participants must be within the age range specified by the study.

Who Cannot Join the Study?

Patients who do not have fibrostenotic Crohn’s disease. This is a type of Crohn’s disease where the intestines become narrowed due to thickening of the walls.
Patients who are not within the specified age range for the study.
Patients who are not part of the specified clinical trial groups.
Patients who are not male or female, as both genders are included in the study.
Patients who are considered part of a vulnerable population, which means they might need special protection or care.

Where you can join this trial?

Verified and Recommended Sites

No sites found in this category

Verified Sites

Site Name	City	Country
Fondazione Policlinico Universitario Agostino Gemelli IRCCS	Rome	Italy
IRCCS Humanitas Research Hospital	Rozzano	Italy
Medical University Of Vienna	Vienna	Austria
Bispebjerg Hospital	Copenhagen	Denmark

Other Sites

Site Name	City	Country
Endoskopia Sp. z o.o.	Sopot	Poland
Virgen del Rocío University Hospital	Sevilla	Spain
Rigshospitalet	Copenhagen	Denmark
Medrise Sp. z o.o.	Lublin	Poland
Fundacio De Recerca Clinic Barcelona-Institut D’Investigacions Biomediques August Pi I Sunyer	Barcelona	Spain
Institut fuer Klinische Transfusionsmedizin und Immungenetik Ulm gGmbH	Ulm	Germany
San Camillo Forlanini Hospital	Rome	Italy
Krankenhaus Waldfriede e.V.	Berlin	Germany
Vita Longa Sp. z o.o.	Katowice	Poland
Odense University Hospital	Odense	Denmark
IRCCS Ospedale Sacro Cuore Don Calabria	Negrar di Valpolicella	Italy
Uniklinikum Salzburg	Salzburg	Austria
Gzdmgmngt Kjmqdyg Rwfenkjdwk Ssgtikdais Ssv ji	Bialystok	Poland
Msuqjzk Utgxetwjxo Oj Gfym	Graz	Austria
Vclbdfom &eyty Vqavalo Ssh z okdz	Wroclaw	Poland
Plkigyy Mtpgpa Swe z Ogon Etb Pqkydzykb	Poniatowa	Poland
Holzxa Hnfomwos	Herlev	Denmark
Auptee Ubrpdnbbod Hqehsoyf	Aarhus	Denmark
Wgv Whcifl Idr Poljm Pqpfusjn Kfcvqun	Warsaw	Poland
Szhczqvinpdwefyudku Biz Uf (poyjielppzzeadtdmkut	Halle (Saale)	Germany

Trial status

Country	Status	Recruitment Start
Austria	Not recruiting	01.08.2023
Denmark	Not recruiting	01.08.2023
Germany	Not recruiting	01.08.2023
Italy	Not recruiting	01.08.2023
Poland	Not recruiting	01.08.2023
Spain	Not recruiting	01.08.2023

Trial locations

Investigated drugs:

ORG-129

AGMB-129 is a medication being studied for its effects on patients with fibrostenotic Crohn’s disease. This condition involves inflammation and scarring in the intestines, which can lead to narrowing and blockages. The trial aims to understand how safe and tolerable AGMB-129 is for patients, as well as how the body processes and responds to the medication.

Investigated diseases:

Crohn's disease

Fibrostenotic Crohn’s Disease – This is a form of Crohn’s disease characterized by the thickening and narrowing of the intestinal walls due to fibrosis and scarring. It primarily affects the digestive tract, leading to symptoms such as abdominal pain, cramping, and bowel obstruction. Over time, the fibrotic tissue can cause strictures, which are narrowings in the intestines that can impede the passage of food. This condition can lead to complications like bowel blockages and may require surgical intervention to relieve the strictures. The progression of fibrostenotic Crohn’s disease can vary, with periods of flare-ups and remission. It is a chronic condition that requires ongoing management to control symptoms and prevent complications.

Trial ID:

2022-502789-26-01

Protocol code:

AGMB-129-C102

Trial Phase:

Therapeutic exploratory (Phase II)

Other Trials to Consider

#1 Clinical Trials Search in Europe

Study on the Safety and Effects of ORG-129 in Patients with Fibrostenotic Crohn’s Disease

What is this study about?

Who Can Join the Study?

Who Cannot Join the Study?